Category: Suggested Reading

All Podcast Categories
S3-E62.1 - Year-End Interview with Mazen Noureddin

S3-E62.1 – Year-End Interview with Mazen Noureddin

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Mazen Noureddin to reflect on opening a new research institute, increasing optimism around drug trials and the use of NITs, work in the novel mitochondrial uncoupling agent HU6, the NAIL-NIT consortium and more.

S3-E60.5 - Madrigal Announcement on Resmetirom: Combination Therapy and Closing Takeaways

S3-E60.5 – Madrigal Announcement on Resmetirom: Combination Therapy and Closing Takeaways

Madrigal announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This final conversation discusses what the announcement could mean for combination therapy and adjacent drug development stories. Each panelist provides closing thoughts to the session, offering diverse perspectives and an array of key takeaways.

S3-E61 - NASH-TAG 2023 Preview with Stephen Harrison

S3-E61 – NASH-TAG 2023 Preview with Stephen Harrison

A highly anticipated NASH-TAG 2023 takes place in Park City, Utah on January 5-7, 2023. In this episode, Stephen Harrison previews the conference agenda and shares his perspective on Madrigal’s announcement of positive topline results from the MAESTRO-NASH trial of resmetirom.

S3-E60.3 - Madrigal Announcement on Resmetirom: Diving into Implications

S3-E60.3 – Madrigal Announcement on Resmetirom: Diving into Implications

This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. This conversation dives into the implications of the Madrigal program, offering compelling commentary from a group of eight panelists with varying perspectives and takeaways.

S3-E60.2 - Madrigal Announcement on Resmetirom: First Reactions and Differing Perspectives

S3-E60.2 – Madrigal Announcement on Resmetirom: First Reactions and Differing Perspectives

This week, Madrigal Pharmaceuticals announced positive topline results from the pivotal Phase 3 MAESTRO-NASH clinical trial of resmetirom for the treatment of NASH and liver fibrosis. To commemorate what is primed to be a major breakthrough for the field, Surfing the NASH Tsunami hosts its largest ever suite of panelists who react to the emerging story. This conversation offers varying first impressions and perspectives from the group of eight.

S3-E59.2 - Year-End Interview with Hannes Hagström

S3-E59.2 – Year-End Interview with Hannes Hagström

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. In this feature, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Hannes Hagström to discuss his studies in 2022 and beyond. Hannes provides an insight-laden tour of the myriad of research directions derived from a population-based cohort of liver disease patients in Sweden.

S3-E59.1 - Year-End Interview with Scott Friedman

S3-E59.1 – Year-End Interview with Scott Friedman

Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this first installment, Surfers Jörn Schattenberg, Louise Campbell and Roger Green are joined by Scott Friedman to discuss the year in review, advancements in liver science, and more.

Experience Nudge Learning! Interested in a new way of learning?